According to a report by Grand View Research, Inc.; the global high resolution melting analysis market is projected to achieve around USD 131.7 billion by 2022. Rising cases of chronic diseases such as cancer, human immunodeficiency virus (HIV), and genetic disorders are anticipated to propel the market over the forecast period (2012 to 2022). High resolution melting analysis (HRMA) techniques strengthen the precision medicine approach towards treatment of various chronic diseases. In addition, advancements in genomics, next generation sequencing, and big data analytics can further strengthen precision medicine approach to treat chronic diseases. This factor is anticipated to positively influence the market in near future.
High prevalence of chronic diseases among geriatric population is anticipated to propel growth of the HRMA market in the forthcoming years. Rising demand for personalized medicines based on genetic combinations and lifestyle can further foster the expansion. Favorable government initiatives to develop healthcare can also fuel growth of the high resolution melting analysis market over the forecast period. Effective properties such as prevention of post polymerase chain reaction (PCR) sample contamination and accuracy of melting profile analysis can drive the market during the forecast period.
The worldwide high resolution melting analysis market can be segregated on the basis of product type, end-use, and region. Based on product type, the market can be classified into reagents, instruments, and software. In 2014, the HRM reagents segment dominated the market. The segment is expected to expand at a CAGR of around 12% during the period. Focus on research and development from academic researchers and universities regarding the treatment of cancer, human immunodeficiency virus (HIV), and other chronic diseases can augment growth of this segment in the coming years.
On the other hand, the HRM instruments segment is expected to witness maximum growth during the forecast period owing to increasing use of HRM analysis for DNA mapping and mutation discovery. In addition, growing investments from private investors owing to growth in clinical laboratories and easy validation of clinical trials can drive growth of this segment in the forthcoming years.
Based on end-use, the high resolution melting analysis market can be divided into clinical diagnostics and academic researcher. In 2014, the academic researchers segment dominated the global market while accounting for around 77.01% revenue share. High demand for efficient and simple molecular diagnostics coupled with technological advancements for conventional genotyping can foster growth of the market. Moreover, high demand for powerful genotype analysis of massive samples for large scale genotyping projects can further impel market growth during the forecast period.
The clinical diagnostics segment is likely to witness the fastest growth in the forthcoming years owing to growth in laboratory automation. In addition, rising cases of human immunodeficiency virus (HIV), cancer, and acquired immune deficiency syndrome (AIDS) can fuel demand for HRM analysis in clinical labs.
Regional segmentation includes Asia Pacific, Europe, Latin America, North America, and Middle East & Africa (MEA). In 2014, North America accounted for the largest market share of 41.6% owing to prevalence of high-end healthcare infrastructure in the region. In addition, increasing investment in R&D activities and availability of favorable reimbursement policies can also fuel the market for high resolution melting analysis in the region. Moreover, rising awareness regarding diagnostic tools available coupled with technological advancements can drive demand for HRMA over the forecast period.
In 2014, Europe accounted for around 37.8% of revenue share followed by North America. Growing investment in R&D owing to high demand for advanced technology in terms of research instruments can augment the high resolution melting analysis market growth in the region. Germany is expected to be the fastest growing market for HRMA and can expand at a CAGR of around 10.1% during the period.
Moreover, the Asia Pacific region is expected to witness maximum growth during the forecast period owing to rising cases of chronic diseases such as cancer. In addition, population explosion and unmet medical requirements can also impel demand for HRMA in this region.
Some of the leading companies in the high resolution melting analysis market are Kapa Biosystems; Roche Molecular Systems; Idaho Technology, Inc.; Thermo Fisher Scientific Corporation; and Bio – Rad Laboratories. The market being oligopolistic in nature includes less number of companies accounting for big market share. Hence, most existing market players are likely to face tough competition from each other. Various organic and inorganic growth methods can support companies to achieve their customer pool.